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Summary  The  seroprevalence  (SP)  of  measles  and  rubella  virus  antibodies  is
presented  by  age  groups  obtained  in  the  IV  Serosurvey  of  the  Region  of  Madrid
(2008—2009).  The  target  population  is  composed  of  residents  with  ages  ranging
between  2  and  60  years  in  the  Region  of  Madrid.  A  two-stage  cluster  sample  is
used.  The  SP  of  measles  virus  antibodies  is  97.8%  (CI  95%:  97.3—98.2).  The  high-
est  SP  is  observed  in  the  2—5  year  and  41—60  year  age  groups.  The  point  estimate
does  not  reach  95%  in  the  16—20  and  21—30  year  age  groups.  The  SP  of  rubella
virus  antibodies  is  97.2%  (CI  95%:  96.5—97.7).  The  SP  is  over  95%  in  all  of  the  age
groups.  In  immigrant  women  between  the  ages  of  16  and  49,  the  SP  is  95.9%  (CI  95%:
93.7—97.4).  The  identiﬁcation  of  groups  susceptible  to  the  measles  virus  in  young
adults  could  lead  to  outbreaks  as  a  result  of  importing  the  virus.  The  circulation  of
the  rubella  virus  is  possible  among  immigrant  women  aged  between  16  and  49  years,
which  could  lead  to  the  appearance  of  SRC  cases.  Epidemiological  surveillance  will
allow  the  impact  on  the  measles  and  rubella  elimination  plan  to  be  determined  in
the  future.
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easles  is  the  most  contagious  disease  with  the
ighest  mortality  in  the  world  among  other  vaccine-
reventable  diseases  [1]. Rubella  can  cause  severe
arm to  a  fetus  when  the  virus  infects  a  suscep-
ible pregnant  woman  [2]. Both  diseases  meet  the
equirements  for  the  elimination  of  a  disease  [3].
The WHO  Region  Committee  for  Europe  has  com-
itted to  eliminate  measles  and  rubella  and  to
revent  congenital  rubella  syndrome  (CRS)  by  the
ear 2015  [4].  To  meet  this  target,  a  high  vaccina-
ion coverage  (95%  or  more)  needs  to  be  reached
nd maintained  with  two  vaccine  doses  for  measles
nd  at  least  one  vaccine  dose  for  rubella.  Likewise,
urveillance systems  that  allow  for  the  detection,
nvestigation and  monitoring  of  all  disease  cases
ust be  available  [4,5].  The  Community  of  Madrid
CM) has  had  high  vaccination  coverage  for  the
MR vaccine  since  1984—1985.  Measles  has  been
n urgently  notiﬁable  disease  since  the  start  of the
easles  Elimination  Plan  in  the  CM  in  2001  [6]  and
ubella  has  been  an  urgently  notiﬁable  disease  since
012.
Serosurveillance  surveys  allow  for  the  protection
evel of  the  population  against  these  diseases  to
e evaluated  and  for  any  susceptible  population
roups to  be  detected  that  could  require  speciﬁc
revention measures.  Four  serosurveys  have  been
arried out  in  the  CM;  all  of  them  used  similar
ethodologies  [7—9]. In  this  study,  the  serosurveil-
ance (SP)  of  measles  and  rubella  virus  antibodies
s presented  by  age  groups  obtained  in  the  IV  Sero-
urvey  (2008—2009),  and  the  SP  of  measles  is  com-
ared  with  the  serosurveillance  that  was  obtained
n the  previous  survey.  The  possible  association  with
ocio-demographic  factors  is  investigated.
ethods
his  study  is  a  transversal  observational  study.  The
arget population  is  composed  of  residents  with
ges ranging  between  2  and  60  years  in  the  CM.
 two-stage  cluster  sample  is  used,  with  stratiﬁca-
ion of  the  ﬁrst  stage  units.  The  sample  framework
s shaped  by  the  public  health  centers  belonging
o the  Madrid  Health  Service,  and  the  population
ttending the  health  service  is distributed  in  basic
ealth  areas.  The  stratiﬁcation  was  carried  out
ccording  to  the  socio-economic  condition  and  per-
entage of  the  immigrant  population.  The  primary
ealthcare  centers  were  selected  in  proportion  to
he size  of  each  stratum.  In  the  second  stage,
he patients  who  attended  the  primary  health  care
enters  between  January  and  June  2008  and  from
R
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ctober  to  December  2009  were  selected  until  each
ample sub-group  size  was  reached.  Each  individ-
al had  a serum  sample  taken  for  analysis,  and
ocio-demographic  data  were  collected  along  with
he immunization  status  through  a questionnaire.
nformed consent  was  obtained  from  all  partic-
pants. The  variables  analyzed  were:  age,  sex,
lace of  origin,  educational  level,  social  class  and
ocumented  vaccine  status.  The  classiﬁcation  of
ocial class  proposed  by  the  Sociedad  Espan˜ola  de
pidemiología  [10]  (Spanish  Epidemiology  Society)
as adopted.  The  serological  samples  were  ana-
yzed at  the  Regional  Public  Health  Laboratory  of
he CM.  The  detection  of  speciﬁc  IgG  antibodies
as carried  out  using  indirect  ELISA  (Enzygnost®
nti-Measles-Virus/IgG  y  Enzygnost® Anti-Rubella-
irus/IgG; Siemens  Healthcare  Diagnostics;  GmbH
arburg  Germany)  and  using  the  Behring  ELISA  Pro-
essor III  system.  Both  quantitative  and  qualitative
gG  results  were  obtained  in  accordance  with  the
anufacturer’s  recommendations.
The  representativeness  of  the  sample  was  evalu-
ted by  comparing  the  distribution  of  the  education
evel and  social  class  in  the  Census  of  Population
nd Housing  (2001)  [11]  and  with  the  population
overed by  the  surveillance  system  of  risk  factors
or non-transmittable  diseases  of  the  CM  (SIVFRENT-
) [12]. The  data  were  weighted  by  age  group,  sex
nd proportion  of  immigrant  population.
The cut-off  point  from  which  a sample  was
onsidered to  be  seropositive  was  150  mUI/ml
or measles  and  4  UI/ml  for  rubella.  The  possible
ssociation with  socio-demographic  factors  was
nalyzed using  logistical  regression,  including  the
ge group  variable  and  variables  with  p  <  0.10
n the  bivariate  analysis.  The  prevalence  ratio
PR) was  used  to  compare  the  data  obtained  in
he current  survey  with  that  from  the  previous
erosurvey (1999—2000).  The  geometric  mean  (GM)
f the  antibody  concentration  was  estimated  by
he age  group  and  vaccine  status.  The  seronegative
ubjects were  assigned  half  of  the  cut-off  point
sed (75  mUI/ml  for  measles  and  2 UI/ml  for
ubella) as  the  GM  in  an  arbitrary  manner.  The  GM
omparison  was  carried  out  using  Student’s  t-test
fter logarithmic  transformation.  The  analysis  was
erformed  using  the  STATA  11.0  program.  The
stimates are  presented  with  a conﬁdence  interval
CI) of  95%.  The  study  was  approved  by  a clinical
esearch ethical  committee.esults
our-thousand  three-hundred  eighty  subjects  par-
icipated, with  a total  response  rate  of  77.0%  and  a
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Table  1  SP  of  measles  and  rubella  virus  antibodies  by  age  group  IV  Serosurveillance  Survey,  2008—2009.  Community
of  Madrid.
Age  n  Measles  Rubella
Prev CI  95%  PR  CI  95%  Prev  CI  95%  PR  CI  95%
2—5y  349  99.7  98.0  100  1  —  —  98.7  96.5  99.5  1  —  —
6—10y  544  97.6  95.2  98.9  0.98  0.97  0.99  98.5  96.7  99.3  0.99  0.98  1.01
11—15y  455  96.4  94.3  97.7  0.96  0.94  0.98  98.9  97.6  99.5  1.00  0.98  1.01
16—20y  732  94.5  92.3  96  0.95  0.93  0.96  98.1  96.9  98.8  0.99  0.98  1.01
21—30y  816  94.3  92.1  96  0.95  0.94  0.97  95.8  94.5  96.8  0.97  0.95  0.99
31—40y  756  98.3  97.1  99  0.98  0.97  1.00  96.9  95.2  98.1  0.98  0.96  1.00
41—60y 728  99.8  99.0  100  1.00  0.99  1.01  97.1  95.8  98.1  0.98  0.96  1.00
Total 4380  97.8 97.3  98.2  97.2  96.5  97.7
rval.
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aPrev = Prevalence; PR = Prevalence ratio; CI = Conﬁdence inte
response  rate  of  75.0%  in  men  and  79.0%  in  women.
This proportion  increases  to  over  80%  in  the  2—20
year  age  groups,  but  it  did  reach  this  ﬁgure  in  the
over 20  years  age  groups.  The  main  reason  for  rejec-
tion is a  lack  of  interest  (52.0%),  followed  by  a
lack of  time  (21.7%).  In  the  SIVFRENT-A  sample,  the
proportion  of  people  with  a  high  socio-economic
level (26.7%)  and  with  university  studies  (35.9%)
is higher  than  that  observed  in  this  survey  (23.7%
and 29.3%,  respectively).  Regarding  the  census,  this
study shows  a  higher  proportion  of  people  with  a
university  level  education  (29.3%  vs.  23.5%).
Measles
The  SP  of  measles  virus  antibodies  in  the  target
population is  97.8%  (CI  95%:  97.3—98.2).  The  high-
est SP  is  observed  in  the  2—5  year  and  41—60  year
age groups  (Table  1  and  Fig.  1).  The  point  esti-
mate does  not  reach  95%  in  the  16—20  or  21—30
year age  groups.  The  SP  of  the  groups  included
g
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Figure  1  SP  (%)  and  GM  (mUI/ml)  of  measles  virus  antibodie
Madrid.etween  6 and  30  years  is  signiﬁcantly  lower  than
hat observed  in  the  2—5  year  age  group.
The  distribution  of  the  GM  antibodies  shows  a
-shaped  pattern,  with  a value  of  2461.63  (CI  95%:
258.15—2683.44)  in  the  2—5  year  age  group,  which
rops to  a minimum  value  in  the  11—15  year  age
roup and  rises  again,  reaching  a maximum  value  in
he 41—60  year  age  group.  The  GM  ratio  between
he 11  and  15  year  age  group  compared  to  the  2—5
ear age  group  is  0.40  (CI  95%:  0.35—0.45)  and  that
f the  41—60  year  age  group  compared  to  the  2—5
ear age  group  is  1.77  (CI  95%:  1.59—1.96).
The current  SP  is  higher  than  that  observed  in
he III  Serosurvey  in  the  2—5  and  6—10  year  age
roups, and  it is  lower  in  the  11—40  year  age  groups
Fig.  1).  The  differences  are  statistically  signiﬁ-
ant in  the  2—5  (PR  =  1.10  (CI  95%:  1.06—1.15))
nd 21—30  (PR  =  0.95  (CI  95%:  0.94—0.97))  year  age
roups.
In the  bivariate  analysis,  values  of  p  < 0.10  are
bserved regarding  sex,  place  of  origin  and  educa-
ional level,  adjusting  by  age  group.  No  statistically
20 años 21-30 años 31-40 años 41-60 años
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Table  2  SP  of  measles  virus  antibodies  by  socio-demographic  variables  IV  Serosurveillance  Survey,  2008—2009.  Community  of  Madrid.
n  Measles  Rubella
%  CI  95% OR  CI  95% %  CI  95% OR  CI  95%
Sex
Women 2288  98.2 97.6 98.7 1  —  —  97.9 97.1  98.5  1  —  —
Men  2092  97.3 96.6 98  0.69 0.46 1.03 96.5 95.5 97.2  0.59  0.39  0.88
Age
2—5y  349  99.7  98  100  1  —  —  98.7  96.5  99.5  1  —  —
6—10y  544  97.6  95.2  98.9  0.12  0.14  0.96  98.5  96.7  99.3  0.87  0.25  2.94
11—15y  455  96.4  94.3  97.7  0.08  0.01  0.66  98.9  97.6  99.5  1.19  0.34  4.16
16—20y  732  94.5  92.3  96  0.06  0.01  0.42  98.1  96.9  98.8  0.69  0.22  2.18
21—30y 816  94.3  92.1  96  0.05  0.01  0.38  95.8  94.5  96.8  0.33  0.12  0.91
31—40y 756  98.3  97.1  99  0.19  0.24  1.46  96.9  95.2  98.1  0.45  0.15  1.3
41—60y  728  99.8  99  100  1.34  0.12  15.7  97.1  95.8  98.1  0.45  0.16  1.27
Immigrant
No  3006  98.1  97.6  98.6  1  —  —  97.5  96.9  98.1  1  —  —
Yes  1374  96.5  95.1  97.5  0.74  0.46  1.2  95.8  94.6  96.8  0.62  0.45  0.85
Educational  level
No  studies  —  1st  level 365  97  94.5 98.4 1  —  —  —  —  —  —  —  —
2nd  level:  1st  cycle  and
Basic  Secondary  Ed.
1359  97.6 96.7 98.3 1.89 0.98 3.64 —  —  —  —  —  —
2nd  level:  2nd  cycle 1367  97.5 96.6 98.1 1.82 0.88 3.74 —  —  —  —  —  —
3rd  level:  University 1222  98.7 97.6 99.3 3.17 1.28 7.87 —  —  —  —  —  —
Total 4380  97.8  97.3  98.2  —  —  —  97.2  96.5  97.7  —  —  —
Prev = Prevalence; PR = Prevalence ratio; CI = Conﬁdence interval.
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Table  3  SP  and  GM  of  measles  virus  antibodies  by  age  group  and  vaccine  status.  IV  Serosurveillance  Survey,
2008—2009.  Community  of  Madrid.
N◦ doses  Age  n  SS  CI  95%  GM  CI  95%
1  dose 2—5y 74  98.7  91.1  99.8  2482.30  2050.09  3005.64
6—10y 47  99.1  93.4  99.9  1200.35  901.85  1597.65
11—15y 28  97.8 84.6 99.7 858.29  553.22  1331.58
16—20y 22  100  —  —  1109.60  756.02  1628.53
2  doses 2—5y 81 100  —  —  2139.89  1782.94  2568.31
6—10y  159  96.0  88.8  98.6  1122.80  949.95  1327.09
11—15y  115  97.2  91.9  99.0  937.10  781.58  1123.57
16—20y  120  97.3  91.8  99.2  960.51  815.63  1131.12
rval.
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signiﬁcant  differences  are  appreciated  as  a  result
of social  class.  In  the  multivariate  model,  it  is
observed  that  the  SP  is  lower  in  men  than  in  women
and is  lower  in  the  immigrant  population  than
in the  native  one,  although  no  statistical  signiﬁ-
cance  exists.  The  SP  is  signiﬁcantly  greater  in  the
group with  a  university  level  education  compared
to the  group  with  a  ﬁrst  or  lower  education  level
(Table  2).
Among individuals  between  the  ages  of  2  and  20
without  any  history  of  measles,  no  differences  are
seen in  the  SP  or  in  the  GM  in  relation  to  the  number
of doses  received  (Table  3).  There  are  also  no  sta-
tistically  signiﬁcant  differences  in  the  SP  related  to
the age  group  regardless  of  the  number  of  doses.
However, a  drop  is  observed  in  the  GM  with  age,
both in  children  who  had  received  1  dose  and  in
those who  had  received  2.  The  GM  ratio  among
the 6—10  and  2—5  year  age  groups  is 0.48  (CI95:
0.35—0.67) for  those  vaccinated  with  a  single  MMR
dose  and  0.52  (CI95:  0.41—0.67)  for  those  vacci-
nated with  two  doses.  Among  individuals  between
the ages  of  6  and  20  years,  no  statistically  signiﬁ-
cant differences  are  observed.
G
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Figure  2  SP  (%)  and  GM  (UI/ml)  of  rubella  virus  antibodies
Madrid.ubella
he  SP  of  rubella  virus  antibodies  in  the  target  pop-
lation is  97.2%  (CI  95%:  96.5—97.7).  The  SP  is  over
5% in  all  of  the  age  groups.  The  lowest  value  is
bserved  in  the  21—30  age  group,  where  the  lower
imit of  the  CI  95%  does  not  reach  this  ﬁgure  (Table  1
nd  Fig.  2). The  differences  in  the  SP  according
o the  age  group  are  very  small  compared  to  that
bserved  in  the  2—5  year  age  group.  The  largest  dif-
erence  is  observed  in  the  21—30  and  31—40  year
ge groups,  which  show  a  lower  SP.  In  women  from
6 to  49  years  of  age,  the  SP  is  98.0%  (ICI  95%:
7.0—98.7).
The distribution  of  the  GM  antibodies  also  shows
 U-shaped  pattern,  with  a  value  of  68.62  (CI
5%: 63.0—74.7)  in  the  2—5  year  age  group,  which
rops to  a minimum  value  in  the  16—20  year  age
roup, rises  again  in  the  21—40  year  age  groups  and
ecreases  in  the  41—60  year  age  group  (Fig.  2).  The
M ratio  between  the  6  and  10  year  age  group  com-
ared to  the  2—5  year  age  group  is  0.68  (CI  95%:
.61—0.76). No  statistically  signiﬁcant  differences
re observed  between  the  GM  for  the  2—5  year  age
20 años 21-30 años 31-40 años 41-60 años
98.1 95.8 96.9 97.1
95.9 98.7 99.1
94.5 98.6 98.5
44.71 56.24 71.83 64.43
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Table  4  SP  and  GM  of  rubella  virus  antibodies  by  age  group  and  vaccine  status.  IV  Serosurveillance  Survey,
2008—2009.  Community  of  Madrid.
N◦ doses  Age  n  SS  CI  95%  GM  CI  95%
1  dose 2—5y 75  98.7  91.2  99.8  73.45  60.37  89.37
6—10y  52  99.2  94.2  99.9  46.47  36.51  59.14
11—15y  43  98.5  89.7  99.8  42.12  30.64  57.89
16—20y 31  100  —  —  49.10  37.02  65.13
2  doses 2—5y 82 100  —  —  70.41  61.69  80.37
6—10y 176  98.3 93.4 99.6 41.78 37.04  47.13
11—15y 124  100  —  —  45.23 39.05  52.39
16—20y  152  98.6  94.4  99.7  39.89  34.49  46.14
Prev = Prevalence; PR = Prevalence ratio; CI = Conﬁdence interval.
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aroup  and  that  for  the  31—40  and  41—60  year  age
roups.
When compared  to  the  previous  survey,  the  dif-
erences in  the  SP  are  very  small  and  only  reach
tatistical signiﬁcance  in  the  2—5  (1.03  (CI  95%:
.01—1.06)) and  6—10  (1.03  (CI  95%:  1.01—1.06))
ear age  groups.  The  point  estimate  of  the  SP  in
omen  between  21  and  45  years  is  lower  than  in
he III  Serosurvey,  but  these  differences  are  not
tatistically  signiﬁcant.
In  the  bivariate  analysis,  values  of  p  <  0.10  are
bserved  regarding  sex,  place  of  origin  and  edu-
ational  level,  adjusting  by  age  group.  In  the
ultivariate  model,  it  is  observed  that  the  SP
s lower  in  men  than  in  women  and  is  lower  in
he immigrant  population  than  in  the  native  one
Table  2).
In native  women  between  the  ages  of  16  and  49,
he SP  is  98.6%  (CI  95%:  97.3—99.3),  and  in  immi-
rant women,  it  is  95.9%  (CI  95%:  93.7—97.4).
Among  individuals  aged  between  2  and  20  years
ithout  a  rubella  history,  the  GM  ratio  for  the  6—10
ear age  group  with  respect  to  that  of  the  2—5  year
ge group  is  0.63  (CI95:  0.47—0.86)  for  those  who
ad received  one  dose  of  MMR  vaccine  and  0.59
CI95: 0.49—0.72)  for  those  who  had  received  two
oses of  the  vaccine  (Table  4).
iscussion
easles
he  SP  of  measles  virus  antibodies  in  the  target  pop-
lation is over  95%,  a  ﬁgure  that  makes  it  possible  to
aintain the  elimination  status  in  our  region.  The
igh SP  in  children  in  the  2—5  year  age  group  and
he increase  observed  compared  to  previous  sur-
eys shows  an  increase  in  vaccine  coverage  over
b
m
m
[ime  as  well  as  a recent  administration  of  the  vac-
ine. The  high  SP  in  people  over  30  years  of  age  is
he result  of  a greater  natural  immunity  in  the  adult
opulation  that  did  not  beneﬁt  from  the  scheduled
mmunization [13].
However,  the  SP  in  the  age  groups  between  6 and
0 years  is  signiﬁcantly  lower  than  that  of  the  2—5
ear age  group.  In  addition,  a drop  is  observed  in
he 11—40  year  age  groups  compared  to  previous
urveys. This  could  be  a reﬂection  of  reduced  vac-
ination  coverage  in  the  older  age  groups  together
ith a decrease  in  the  circulation  of  the  virus  and
herefore  in  natural  immunity.  The  drop  of  the
P in  the  6—10  and  11—15  year  age  groups  may
lso indicate  a decrease  in  vaccine  immunity  over
ime. The  decrease  in  the  GM  of  antibodies  with
ge, regardless  of  the  number  of  vaccine  doses
eceived, is  compatible  with  the  latter  explanation.
he point  estimate  of  the  SP  does  not  reach  95%
n the  16—20  and  21—30  year  age  groups,  meaning
hat, in  these  groups,  there  is  a larger  proportion
f individuals  susceptible  to  suffering  and  transmit-
ing  the  infection.  In  a recent  study  carried  out  in
adrid, an  SP  below  that  recommended  by  the  WHO
n young  adults  [14]  was  also  observed.  These  data
re compatible  with  community-wide  measles  out-
reaks that  have  occurred  in  recent  years  and  that
ave speciﬁcally  affected  the  young  adult  popula-
ion [15].
The U-shaped  pattern  of  the  distribution  of  MG
s similar  to  the  distribution  of  the  SP  by  age  group.
t is  worth  mentioning  that  the  GM  of  antibod-
es in  people  over  30  years  of  age  is  greater  than
hat for  the  2—5  year  age  group,  which  is  prob-
bly related  to  a different  level  of  exposure  to
oth the  vaccine  and  the  wild  viruses,  but  it  also
ay indicate  that  the  natural  infection  causes  a
ore intense  immune  response  than  vaccination
16—18].
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The  multivariate  analysis  shows  that  the  SP  is
lower  in  men  and  in  the  immigrant  population,
although the  differences  are  not  statistically  sig-
niﬁcant.  The  greater  susceptibility  in  men  and  in
the immigrant  population  has  been  described  in
other studies  [19].  Likewise,  there  are  statistically
signiﬁcant differences  regarding  education  level,
although  the  prevalence  of  antibodies  is  over  95%  at
all levels.  The  SP  increases  as  the  educational  lev-
els increases,  as  opposed  to  that  observed  in  a study
performed  in  Germany,  where  the  children  of  moth-
ers with  higher  education  levels  showed  greater
susceptibility [20].
The administration  of  a  second  vaccine  dose  does
not mean  an  increase  in  the  quantitative  levels
of antibodies.  However,  a  statistically  signiﬁcant
decrease in  the  GM  is observed  with  age.  This  drop
is followed  by  an  increase  in  the  16—20  year  age
group, which  can  be  explained  by  a higher  natural
immunity component  in  this  group  that  is  because
of vaccine  coverages  that  were  not  high  enough  in
these age  cohorts.  The  decrease  in  the  GM  does  not
seem to  have  an  effect  on  the  SP  of  the  antibodies.
A study  carried  out  in  Luxemburg  shows  a  rapid  drop
in the  antibody  titers  in  vaccinated  people  with  high
titers, but  a  stable  trend  of  antibody  titers  in  vac-
cinated  people  with  low  titers,  which  suggests  that
few vaccinated  individuals  will  become  suscepti-
ble [21].  In  our  study,  no  differences  are  detected
among the  age  groups  from  6 to  20  years  of  age,  a
fact that  is compatible  with  the  described  trend.  It
must be  taken  into  account  that  the  data  analysis
according to  the  vaccine  status  may  be  inﬂuenced
by the  low  proportion  of  participants  with  a known
vaccine  status  and  the  validity  of  parents’  memo-
ries regarding  the  history  of  their  children  who  had
measles.
A drop  in  immunity  over  time  has  been  observed
in several  studies  [16,19,21—25], and  it  may  repre-
sent  the  need  for  additional  doses  of  MMR  vaccine  in
the context  of  minimal  virus  circulation  and  in  the
absence of  a  natural  booster.  However,  the  immune
memory mechanisms  may  play  an  important  role  in
protection after  re-exposure  to  the  virus  and  must
be taken  into  account  [26—28]. Therefore,  the  pres-
ence of  low  Ig  G  antibody  titers  is not  necessarily
equivalent  to  susceptibility  to  the  infection.
Rubella
The  SP  of  rubella  virus  antibodies  is  over  95%  in  all
of the  age  groups.  In  the  immigrant  female  popu-
lation belonging  to  the  16—49  year  age  group,  the
lower  limit  of  the  IC  is  below  95%;  therefore,  the
circulation  of  an  imported  virus  can  affect  this  pop-
ulation group  again  [29]. A  recent  study  carried  out
F
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n  Madrid  shows  an  SP  of  rubella  virus  antibodies
elow 95%  in  young  adults  [14].
Although  a  drop  in  the  SP  and  the  GM  is  observed
y age  groups  in  relation  to  the  2—5  year  age  group,
his is  lower  than  in  the  case  of  measles.  The  GM
f antibodies  in  people  over  30  years  of  age  is
imilar  to  that  of  the  2—5  year  age  group,  which
ay indicate  that  the  level  of  exposure  to  both
he vaccine  and  the  wild  viruses  is  similar,  but  it
lso may  indicate  that  the  immune  response  of  the
accine is  similar  to  that  produced  by  the  natural
nfection.
Regarding  the  previous  survey,  the  drop  in  the
oint estimate  from  21  years  of  age  onwards  is
orth mentioning;  as  with  measles,  this  drop  may
ndicate  a drop  in  the  virus  circulation  and  the  pres-
nce of  cohorts  with  a less  vaccine  and  a reduced
atural immunity  [19,26].
The higher  susceptibility  in  men  and  in  the
mmigrant population  has  also  been  described  for
easles, as  was  mentioned  previously  [19].
As occurs  with  measles,  a drop  in  the  GM  with
ge is  observed  [23,19],  regardless  of  the  number
f vaccine  doses  received,  although  this  drop  is
ot reﬂected  in  the  SP  of  antibodies  and  remains
table in  all  of  the  age  groups  between  6  and  20
ears, which  may  indicate  long-lasting  immunity.
his drop  is  lower  than  that  observed  for  measles,
hich coincides  with  the  results  from  other
tudies [23].
onclusion
he  identiﬁcation  of  groups  that  are  susceptible  to
he measles  virus  in  the  late  adolescent  popula-
ion and  in  young  adults  could  cause  outbreaks  as
 result  of  the  importation  of  the  virus.  Therefore,
oth MMR  vaccination  and  epidemiological  surveil-
ance  need  to  be  reinforced,  particularly  in  these
ge groups.  The  circulation  of  the  rubella  virus  is
ossible among  immigrant  women  in  the  16—49  year
ge group,  which  could  cause  the  appearance  of
ases of  SRC.  The  drop  in  the  level  of  antibod-
es over  time  could  lead  to  the  loss  of  immune
rotection against  the  virus.  In  the  future,  epidemi-
logical  surveillance  will  allow  us  to  determine  the
mpact of the  substitution  of  the  population  cohorts
ith natural  immunity  by  vaccinated  population
ohorts on  the  measles  and  rubella  elimination
lan.unding
o  funding  sources.
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